A series of cardiometabolic-related news items has been observed from Dexcom, Lilly/CVS Caremark, Tidepool, Samsung, and the French Ministry of Health. Below, FENIX provides highlights and insights for the respective news items.
With ADA 2026 approaching (June 5-8; New Orleans, LA), FENIX has compiled a shortlist of key sessions and presentations that warrant close attention across the meeting. While ADA brings new data and fresh perspectives across the cardiometabolic space each year, the list below focuses exclusively on the sessions with potential to shape this year’s conference narrative and ultimately, have an outsized impact on the field for years to come.
A series of cardiometabolic-related news items has been observed from Lilly, Ionis, FDA, and Lannett. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from EMA, Lilly, Beta Bionics, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: Lilly announced topline TRIUMPH-1 data with retatrutide exhibiting up to -30% weight loss (view press release); and Bayer’s Kerendia received FDA priority review in T1DM-associated CKD (view press release). Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Apotex launched generic semaglutide in Canada (view press release); Roche posted a Ph2 obesity combination study (view CT.gov record); and Lilly posted a new macupatide + eloralintide combination study (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: FDA issued a warning letter to ProRx regarding GLP-1RA compounding (view FDA letter) and Lilly partnered with UNICEF (view press release). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from FDA, Novo Nordisk, Altimmune, Lilly, and Insulet. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Sanofi, Zealand Pharma, GSK, Lilly, and Roche. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Lilly, Viking Therapeutics, Merck, and FDA. Below, FENIX provides highlights and insights for the respective news items.